Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
These proteins comprise several major families of receptor tyrosine kinases (VEGFR, PDGFR, FGFR, FLT3) and non-receptor tyrosine kinases (Src-family, Lck). They regulate critical cellular processes including proliferation, differentiation, angiogenesis, and immune cell signaling. Aberrant activity, mutation, or overexpression of these kinases is implicated in a wide spectrum of human diseases, most notably cancer (e.g., acute myeloid leukemia for FLT3, breast cancer for VEGFR and PDGFR, and solid and hematological tumors for FGFR and Src-family kinases). They are important targets for several approved drugs, but therapeutic challenges include off-target effects, resistance, and biomarker selection for effective therapy. The query incorrectly combines these distinct proteins/families, as there is no single molecule or receptor with this combined name.
Inhibition of kinase activity (by small molecule or antibody); Blockade of ligand binding or receptor dimerization; Downregulation of malignant signaling pathways
13 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on VEGFRs, PDGFRs, FGFRs, Src-family kinases, FLT3, Lck (N/A).